These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28913669)

  • 1. Resolving distinct molecular origins for copper effects on PAI-1.
    Bucci JC; McClintock CS; Chu Y; Ware GL; McConnell KD; Emerson JP; Peterson CB
    J Biol Inorg Chem; 2017 Oct; 22(7):1123-1135. PubMed ID: 28913669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
    Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
    Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.
    Chu Y; Bucci JC; Peterson CB
    Protein Sci; 2021 Mar; 30(3):597-612. PubMed ID: 33345392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.
    Thompson LC; Goswami S; Ginsberg DS; Day DE; Verhamme IM; Peterson CB
    Protein Sci; 2011 Feb; 20(2):353-65. PubMed ID: 21280127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.
    Trelle MB; Hirschberg D; Jansson A; Ploug M; Roepstorff P; Andreasen PA; Jørgensen TJ
    Biochemistry; 2012 Oct; 51(41):8256-66. PubMed ID: 22957734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.
    Thompson LC; Goswami S; Peterson CB
    Protein Sci; 2011 Feb; 20(2):366-78. PubMed ID: 21280128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.
    Schar CR; Jensen JK; Christensen A; Blouse GE; Andreasen PA; Peterson CB
    J Biol Chem; 2008 Oct; 283(42):28487-96. PubMed ID: 18658131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
    Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
    Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
    Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
    J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.
    Chu Y; Bucci JC; Peterson CB
    Protein Sci; 2020 Feb; 29(2):494-508. PubMed ID: 31682300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
    J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin.
    Jensen S; Kirkegaard T; Pedersen KE; Busse M; Preissner KT; Rodenburg KW; Andreasen PA
    Biochim Biophys Acta; 2002 Jun; 1597(2):301-10. PubMed ID: 12044908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin.
    Deng G; Royle G; Wang S; Crain K; Loskutoff DJ
    J Biol Chem; 1996 May; 271(22):12716-23. PubMed ID: 8662688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
    Jankun J; Specht Z; Szkudlarek M; Greenfield R; Gaikwad B; Trifonov L; Vaugeois J; Aleem AM; Basrur V; Selman SH; Zavodszky MI; Skrzypczak-Jankun E
    Int J Mol Med; 2006 Mar; 17(3):437-47. PubMed ID: 16465390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
    Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
    Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.